TCIM
NAVB

TIAA CREF Investment Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

TIAA CREF Investment Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-24,732
Closed -$467K – 3225
2016
Q1 		$467K Hold
24,732
– – ﹤0.01% 2807
2015
Q4 		$658K Sell
24,732
-1,639
-6% -$56.9K ﹤0.01% 2798
2015
Q3 		$1.2M Hold
26,371
– – ﹤0.01% 2455
2015
Q2 		$849K Sell
26,371
-656
-2% -$19.1K ﹤0.01% 2774
2015
Q1 		$859K Hold
27,027
– – ﹤0.01% 2695
2014
Q4 		$1.02M Sell
27,027
-423
-2% -$11.6K ﹤0.01% 2637
2014
Q3 		$725K Sell
27,450
-843
-3% -$22.3K ﹤0.01% 2811
2014
Q2 		$837K Buy
28,293
+4,983
+21% +$161K ﹤0.01% 2823
2014
Q1 		$862K Hold
23,310
– – ﹤0.01% 2723
2013
Q4 		$965K Sell
23,310
-1,325
-5% -$51.8K ﹤0.01% 2693
2013
Q3 		$1.31M Buy
24,635
+600
+2% +$35K ﹤0.01% 2459
2013
Q2 		$1.28M Buy
+24,035
New +$1.2M ﹤0.01% 2423

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TIAA CREF Investment Management's NAVB Position: Q2 2016 in Review

TIAA CREF Investment Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 24,732 shares — an estimated $467K sold.

TIAA CREF Investment Management first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $1.31M in Q3 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

  • TIAA CREF Investment Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 24,732 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $467K.
  • TIAA CREF Investment Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
  • TIAA CREF Investment Management's Navidea Biopharmaceuticals Inc. position peaked at $1.31M in Q3 2013.
  • 63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on TIAA CREF Investment Management's 13F filing for Q2 2016, filed 11 Aug 2016.